Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,038.06 -1.94 (-0.19%)
Streaming Delayed Price Updated: 3:50 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
News headline image
This Eli Lilly Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
2 Monster Stocks in the Making ↗
There might still be time to get in on the ground floor. 
Via The Motley Fool
News headline image
2 Growth Stocks with All-Star Potential and 1 We Question
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
News headline image
3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs ↗
For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades. 
Via The Motley Fool
Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Prices ↗
Via Stocktwits
Topics Government
News headline image
The Algorithmic Imperative: Navigating AI’s Ethical Labyrinth in American Healthcare
As of November 2025, Artificial Intelligence (AI) has rapidly transitioned from a futuristic concept to an indispensable tool in American healthcare, profoundly reshaping diagnostics, treatment, and... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Is There a Future for Viking Therapeutics? ↗
The weight loss drug company was counted out far too early in the summer, but investors are warming to it again. 
Via The Motley Fool
News headline image
Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump ↗
The companies announced a huge deal that will have implications for investors. 
Via The Motley Fool
Topics World Trade
News headline image
Organon (OGN) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Monday before market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Eli Lilly And These AI Plays Lead 5 Stocks Near Buy Points ↗
Eli Lilly stock and a pair of AI plays lead this watch list of stocks near buy points as the S&P 500 makes a stand at a key support level. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
News headline image
This Unstoppable Growth Stock Just Gave Investors More Reasons to Buy ↗
The stock didn't stay down for too long. 
Via The Motley Fool
News headline image
Prediction: Eli Lilly Will Be Worth More Than Berkshire Hathaway by 2030 ↗
It could become the first trillion-dollar pharmaceutical company in the process. 
Via The Motley Fool
News headline image
Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors. ↗
Weight loss drugs generated about $10 billion for Lilly in the most recent quarter. 
Via The Motley Fool
Topics Government
News headline image
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance ↗
Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard." 
Via Benzinga
News headline image
Why Novo Nordisk Stock Is Sinking This Week ↗
The global drugmaker is facing some headwinds related to tough competition. 
Via The Motley Fool
Topics Government World Trade
News headline image
Why Nvidia (NVDA) Stock Is Falling Today
Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA) fell 4.1% in the afternoon session after the stock retreated amid renewed concerns about stretched valuations in the AI space and... 
Via StockStory
Topics Artificial Intelligence
News headline image
S&P 500: The Bull Market Is Just Getting Started
The S&P 500 has been on an impressive ascent, with market sentiment in November 2025 largely skewed towards cautious optimism. After a robust year of gains, driven significantly by the "mania around... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment ↗
Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment. 
Via Benzinga
News headline image
Navigating the Shifting Tides: Experts Chart Course for 2025 Stock Market
As the calendar turns towards late 2025, leading financial experts are providing a detailed compass for investors, navigating a stock market characterized by cautious optimism, elevated valuations, and... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included ↗
FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs. 
Via Benzinga
News headline image
Eli Lilly’s Weight-Loss Drug Mounjaro Becomes India’s Top-Selling Medicine By Value: Report ↗
The drug has surpassed GlaxoSmithKline’s antibiotic Augmentin, according to a Reuters report on Friday, citing data from research firm Pharmarack. 
Via Stocktwits
Topics Government
News headline image
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned. 
Via Investor's Business Daily
Topics Government
News headline image
Eli Lilly Stock Defies Trump’s GLP-1 Pricing Pressure With 6-Day Rally As Wall Street Cheers FDA Boost And New Weight-Loss Drug Data ↗
Bank of America Securities called Lilly’s GLP-1 pricing deal “probably a good tradeoff overall,” keeping a ‘Buy’ rating and $950 target. 
Via Stocktwits
Topics Government World Trade
News headline image
Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced ↗
Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage. 
Via Stocktwits
Topics Government World Trade
News headline image
Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts ↗
Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026. 
Via Benzinga
Topics Government
News headline image
Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx ↗
The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026. 
Via Benzinga
Topics Government
News headline image
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know. ↗
Is the fourth time the charm for this Danish pharmaceutical giant? 
Via The Motley Fool
Topics Earnings
News headline image
Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo ↗
The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their obesity drugs. 
Via Investor's Business Daily
Topics Government
News headline image
Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns
The third-quarter 2025 earnings season, largely drawing to a close in early November, has proven to be a dynamic and often surprising period for investors. While a significant majority of S&P 500... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025.... 
Via MarketMinute
Topics Intellectual Property
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.